Close Menu
Home › Almac NGS-Based CDx Gets CE Mark

Almac NGS-Based CDx Gets CE Mark

Jun 05, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Almac Diagnostic Services today announced that it has received CE marking for a next-generation sequencing-based diagnostic assay that will be used to determine molecular eligibility for enrolling patients in a pivotal Phase 2 portion of a cancer drug clinical trial.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sep
16
Featured Webinar

Using Next-Generation Sequencing to Detect Genomic Mutations in Hematologic Malignancies

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.

Oct
03
Featured Webinar

Streamlined and High-Precision Cancer Analysis Using an Automated NGS Workflow in the Reference Lab Setting

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Molecular Diagnostics

  1. USPSTF Formalizes Slightly Expanded BRCA Screening Recommendations

  2. Genentech's Rozlytrek Garners FDA Approval in NTRK-Positive Cancers for Adults, Adolescents

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.